Publications

Comprehensive PubMed List

Selected Publications from 2000 to Present:

Ulrich JD, Ulland TK, Colonna M, Holtzman DM.  Elucidating the Role of TREM2 in Alzheimer’s Disease. Neuron. 2017 Apr 19;94(2):237-248. doi: 10.1016/j.neuron.2017.02.042. Review. PMID:  28426958

 Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, Miller BL, Kerwin DR, Gallardo G, Stewart F, Finn MB, Cairns NJ, Verghese PB, Fogelman I, West T, Braunstein J, Robinson G, Keyser J, Roh J, Knapik SS, Hu Y, Holtzman DM.  Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci Transl Med. 2017 Apr 19;9(386). pii: eaal2029. doi: 10.1126/scitranslmed.aal2029. PMID: 28424326

 

Ising C, Gallardo G, Leyns CEG, Wong CH, Stewart F, Koscal LJ, Roh J, Robinson GO, Remolina Serrano J, Holtzman DM.

AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.

J Exp Med. 2017 Apr 17. pii: jem.20162125. doi: 10.1084/jem.20162125. [Epub ahead of print] PMID: 28416651

Macauley SL, Stanley M, Caesar EE, Yamada SA, Raichle ME, Perez R, Mahan TE, Sutphen CL, Holtzman DM. Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo. J Clin Invest. 2015 May 4. pii: 79742. doi: 10.1172/JCI79742

Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI Holtzman DM. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Annals Clin. Transl. Neurology 2015 Article first published online : 23 JAN 2015, DOI: 10.1002/acn3.176

Roh JH, Jiang H, Finn MB, Stewart FR, Mahan TE, Cirrito JR, Heda A, Snider BJ, Li M, Yanagisawa M, de Lecea L, Holtzman DM. Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease. J Exp Med. 2014 Dec 15;211(13):2487-96. doi: 10.1084/jem.20141788.

Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M,Holtzman DM. Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegeneration 2014 Jun 3;9:20. doi: 10.1186/1750-1326-9-20.

Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgräfe K, Mandelkow EM, Holtzman DM. (2013)Neuronal activity regulates extracellular tau in vivo. J Exp Med. 2014 Mar 10;211(3):387-93

Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, Culver JP, Betensky R, Wozniak DF, Hyman BT, Holtzman DM. (2014) Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis. J. Neurosci. 34(21):7281-92.

Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DMApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci U S A. 2013 Apr 25. [Epub ahead of print] PMID: 23620513

Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener. 2013 Apr 19;8(1):13. [Epub ahead of print] PMID: 23601557

Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, Morris JC,Holtzman DM. Sleep Quality and Preclinical Alzheimer Disease. JAMA Neurol. 2013 Mar 11:1-7. doi: 10.1001/jamaneurol.2013.2334.

Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI,Holtzman DM. (2013) Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo.Neuron 80: 402-414

Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM,Holtzman DM. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. J Exp Med. 2012 Nov 19;209(12):2149-56. doi: 10.1084/jem.20121274. Epub 2012 Nov 5.

Kfoury N, Holmes BB, Jiang H,Holtzman DM, Diamond MI. Trans-cellular Propagation of Tau Aggregation by Fibrillar Species. J Biol Chem. 2012 Jun 1;287(23):19440-51. Epub 2012 Mar 29.

Basak JM, Verghese PB, Yoon H, Kim J,Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. J Biol Chem. 2012 Apr 20;287(17):13959-71. Epub 2012 Mar 1.

Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP,Holtzman DM. Bidirectional relationship between functional connectivity and amyloid-β deposition in mouse brain. J Neurosci. 2012 Mar 28;32(13):4334-40.

Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. (2012) Disruption of the sleep-wake cycle and diurnal fluctuation of amyloid-β in mice with Alzheimer’s disease pathology. Science Translational Medicine . 5:150ra122.                                              Abstract | Reprint |  Full Text

Holtzman DM, Goate A, Kelly J, Sperling R. Mapping the road forward in Alzheimer’s disease. Sci Transl Med. 2011 Dec 21;3(114):114ps48.

Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM. Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis. J Neurosci. 2011 Dec 7;31(49):18007-12.

Verghese PB, Sasaki Y, Yang D, Stewart F, Sabar F, Finn MB, Wroge CM, Mennerick S, Neil JJ, Milbrandt J, Holtzman DM. Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19054-9. Epub 2011 Nov 4.

Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM.In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice.
J Neurosci. 2011 Sep 14;31(37):13110-7.

Tarawneh R, D’Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol. 2011 Aug;70(2):274-85. doi: 10.1002/ana.22448.

Castellano JM, Kim J, Stewart FR, Hong J, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. (2011) Human apoE Isoforms Differentially Regulate Brain Amyloid-? Peptide Clearance. Science Translational Medicine Jun 29;3(89):89ra57.

Tarawneh R, D’Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee J.M. MD, PhD, Morris JC, Holtzman DM. (2011) Visinin-like protein-1: Diagnostic and Prognostic Biomarker in Alzheimer’s Disease. Ann Neurol. Published online April 7, 2011, DOI: 10.1002/ana.22448

Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-? deposition. Nat Neuroscience 2011 14(6):750-6.

Dietrich HH, Xiang C, Han BH, Zipfel GJ, Holtzman DM. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol Neurodegener. 2010 Apr 13;5:15.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010 Jan;67(1):122-31.

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D’Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM. (2010) YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer’s Disease. Biol. Psychiatry 68:903-912

Zeng LH, Bero AW, Zhang B, Holtzman DM, Wong M. Modulation of Astrocyte Glutamate Transporters Decreases Seizures in a Mouse Model of Tuberous Sclerosis Complex.
Neurobiol Dis. 2009 Dec 29. [Epub ahead of print]

Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah A, Schmidt RE, Perry A, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh Compound B Detection of CerebralAmyloid Beta in a Patient With Clinical, Cognitive, and Cerebrospinal FluidMarkers of Alzheimer Disease. Arch Neurol. 2009 Dec;66(12):1557-1562.

Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P, St George Hyslop P, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S. Acute dosing of latrepirdine (DimebonTM), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener. 2009 Dec 17;4(1):51. [Epub ahead of print]

Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, Shah AR, Kauwe JS. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease.
Neurology. 2009 Dec 8;73(23):1982-7. Epub 2009 Nov 11.

Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009 Dec;66(12):1557-62.

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009 Dec;66(12):1469-75.

Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. 2009) Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular A? Clearance. Neuron. 2009 Dec 10;64(5):632-44.

Holtzman DM. Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization. Arch Neurol. 2009 Dec;66(12):1552-3.

Hinrichs AL, Mintun MA, Head D, Fagan AM, Holtzman DM, Morris JC, Goate AM. Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer’s Disease. Biol Psychiatry. 2009 Nov 4. [Epub ahead of print]

Duchek JM, Balota DA, Tse CS, Holtzman DM, Fagan AM, Goate AM. The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer’s disease. Neuropsychology. 2009 Nov;23(6):746-58.

Lodygensky G, West T, Stump M, Holtzman DM, Inder T, Neil J. In vivo MRI analysis of an inflammatory injury in the developing brain. Brain Behav Immun. 2009 Nov 26. [Epub ahead of print]

Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease.
EMBO Mol Med. 2009 Nov;1(8-9):371-80.

Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease.Nature. 2009 Oct 15;461(7266):916-22.

Kim J, Basak JM, Holtzman DM. (2009) The role of apolipoprotein E in Alzheimer’s disease. Neuron. Aug 13;63(3):287-303. PMID: 19679070

Aslund A, Sigurdson CJ, Klingstedt T, Grathwohl S, Bolmont T, Dickstein DL, Glimsdal E, Prokop S, Lindgren M, Konradsson P, Holtzman DM, Hof PR, Heppner FL, Gandy S, Jucker M, Aguzzi A, HammarstroÌ?m P, Nilsson KP. (2009) Novel Pentameric Thiophene Derivatives for in Vitro and in Vivo Optical Imaging of a Plethora of Protein Aggregates in Cerebral Amyloidoses. ACS Chem Biol. Jul 30. [Epub ahead of print] PMID: 19624097

Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T. (2009) Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc Natl Acad Sci USA Jul 21;106(29):12145-50. Epub 2009 Jul 6. PMID: 19581601

Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H. (2009) Caffeine Suppresses Amyloid-beta Levels in Plasma and Brain of Alzheimer’s Disease Transgenic Mice. J Alzheimers Dis. Jul;17(3):681-97. PMID: 19581723

Holtzman DM. A surrogate marker for Abeta42 production in the CNS.. EMBO Mol Med. 2009 Jul;1(4):195-7.

Yuede CM, Zimmerman SD, Dong H, Kling MJ, Bero AW, Holtzman DM, Timson BF, Csernansky JG. (2009) Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer’s disease. Neurobiol Dis. 35(3):426-32. Epub 2009 Jun 12.

West T, Stump S, Lodygensky G, Neil JJ, Deshmukh M Holtzman DM. (2009) Lack of X-linked inhibitor of apoptosis protein leads to increased apoptosis and tissue loss following neonatal hypoxic-ischemic brain injury. ASN Neuro. Apr 14;1(1). pii: e00004. doi: 10.1042/AN20090005. PMID: 19570023

Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE. 2009 Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci. Apr 1;29(13):4252-62. PMID: 19339619

Tarawneh R, Holtzman DM. (2009) Critical issues for successful immunotherapy in Alzheimer’s disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets. Apr;8(2):144-59. PMID: 19355934

Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. Feb;65(2):176-83.

Perrin RJ, Fagan AM, Holtzman DM. (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature. 461:916-22.

1Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.Ann Neurol. 66(1):48-54. PMID: 19360898

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM. (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol. 66(5):638-45.

Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. (2009) Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 29(34):10706-14.

Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. (2009) Amyloid- ? Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science. DOI: 10.1126/science.1180962
(Download the pdf of this paper here)

Brody DL, Holtzman DM. Active and Passive Immunotherapy for Neurodegenerative Disorders. Annu Rev Neurosci. 2008 Mar 19. [Epub ahead of print] PMID: 18352830

Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008 Jan 17; [Epub ahead of print], 118(2):671-682.

Cirrito JR, Kang J-E, LeeJ, Stewart FR,­­Verges D, Silverio LM BuG, MennerickS, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-b in vivo. Neuron 2008 58:42-51.

Holtzman DM. (2008) Alzheimer’s disease: Moving towards a vaccine. Nature 24;454(7203):418-20. PMID: 18650906

Brody DL, Magnoni S, Schwetye KE, Spinner M, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. (2008) Amyloid-? Dynamics Correlate with Neurological Status in the Injured Human Brain Science 321:1221 – 1224. PMID: 18755980

Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM. 2008 Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci. 28(52):14156-64. PMID: 19109498

Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity.Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10673-8. Epub 2007 Jun 5

Wahrle SE, Shah AR, Fagan AM, Smemo S, Kauwe JS, Grupe A, Hinrichs A, Mayo K, Jiang H, Thal LJ, Goate AM, Holtzman DM. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener. 2007 Apr 12;2:7. PMID: 17430597

Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.
Neurology. 2007 Feb 27;68(9):666-9. PMID: 17325273 [PubMed – indexed for MEDLINE]

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

West T, Atzeva M, Holtzman DM. Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury. Dev Neurosci. 2007;29(4-5):363-72.

Hartman RE, Shah A, Fagan AM, Schwetye KE, Parsadanian M, Schulman RN, Finn MB, Holtzman DM.Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer’s disease.Neurobiol Dis. 2006 Dec;24(3):506-15. Epub 2006 Sep 28.

Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006 Jul;12(7):856-61. Epub 2006 Jun 25.

Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
Ann Neurol. 2006 Mar;59(3):512-9. PMID: 16372280 [PubMed – indexed for MEDLINE]

Brody D, Holtzman DM. (2006) Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury.Exp Neurol. 197(2):330-40.

West T, Atzeva M, Holtzman DM (2006) Caspase-3 deficiency during development increases vulnerability to hypoxic-ischemic injury through caspase-3-independent pathways. Neurobiol Dis. 22(3):523-37.

Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT, Holtzman DM. Anti- Ab antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005; 115: 428-433.

Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O’Dell MA, Fagan AM, Lashuel HA, Walz T, Asai K, Holtzman DM. (2005) Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-b. Neurobiology of Disease 19:66-76.

Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. (2005) Human apolipoprotein E4 alters the amyloid-b 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. Journal of Neuroscience 25:2803-2810.

Loren DJ, Seeram NP, Schulman RN, Holtzman DM. (2005) Maternal Dietary Supplementation with Pomegranate Juice Is Neuroprotective in an Animal Model of Neonatal Hypoxic-Ischemic Brain Injury. Pediatric Research 57:858-864.

Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. (2005)
Treatment with an amyloid-b antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer’s disease. Journal of Neuroscience 25: 6213 – 6220.

Hu Y, Townsend RR, Fagan AM, Holtzman DM. (2005) Comparative proteomic analysis of intra- and inter-individual variation in human cerebrospinal fluid. Molecular and Cellular Proteomics 4(12):2000-9.

Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM (2005) Deletion of Abca1 increases Ab deposition in the PDAPP transgenic mouse model of Alzheimer’s disease Journal of Biological Chemistry 280(52):43236-43242.

Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-b deposition in an Alzheimer’s disease mouse model. J. Clin. Invest. 115: 3285 – 3290.

Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. (2005) Synaptic activity regulates interstitial fluid amyloid-b levels in vivo. Neuron 48(6):913-922.

DeMattos R, Cirrito J, O’Dell M, Taylor J, Harmony J, Aronow B, Bales K, Paul S, Holtzman DM. (2004) ApoE and clusterin cooperative suppress Ab levels and deposition: Evidence that ApoE regulates extracellular Ab metabolism in vivo. Neuron 41:193-202.

Wahrle, SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T and Holtzman, DM (2004) ABCA1 is required for normal CNS apoE levels and for lipidation of astrocyte-secreted apoE. Journal of Biological Chemistry 279(39):40987-20993.

Brendza RP, O’Brien C, Simmons K, McKeel DW, Bales KR, Paul SM, Olney JW, Sanes JR,, Holtzman DM. (2003) PDAPP;YFP double transgenic mice: A tool to study amyloid-b associated changes in axonal, dendritic, and synaptic structure. J. Comp. Neurol. 456:375-383.

Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM (2003) Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in APP transgenic mice. Journal of Neuroscience 23: 7889-7896.

Cirrito JR, May PC, O’Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-b metabolism and half-life. Journal of Neuroscience 23:8844-8853.

DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. (2002) Brain to plasma amyloid-b efflux: A measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science 295:2264-2267.

DeMattos RB, Bales KR, Kierson ME, O’Dell MA, Foss EM, Paul SM, Holtzman DM. (2002) Plaque associated disruption of CSF and plasma Ab equilibrium in a mouse model of Alzheimer’s disease. J. Neurochem. 81:229-236.

Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. (2002) Human and murine apoE markedly influence Ab metabolism before and after plaque formation in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 9:305-318.

Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. (2002) Immunization reverses memory deficits without reducing Ab burden in Alzheimer’s disease model. Nature Neurosci. 5:452-457.

Han BH, Xu D, Choi J, Han Y, Xanthoudakis S, Roy S, Tam J, Vaillancourt J, Colucci J, Siman R, Giroux A, Robertson GS, Zamboni R, Nicholson DW, Holtzman DM. (2002) Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death following neonatal hypoxic-ischemic brain injury. J. Biol. Chem. 277:30128-30136.

Arvin KL, Han BH, Du Y, Lin S, Paul SM, Holtzman DM. (2002) Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann. Neurol. 52:54-61.

DeMattos RB, O’Dell MA, Parsadanian M, Taylor JW, Harmony JAK, Bales KR, Paul SM, Aronow BJ, Holtzman DM. (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 99:10843-10848. (10.1073/pnas.162228299)

Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK, Holtzman DM. (2002) APOE4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer’s disease. J. Neurosci. 22:10083-10087.

Han BH, DeMattos RB, Dugan LL, Kim-Han JS, Brendza R, Fryer JD, Kierson M, Cirrito J, Quick K, Harmony JAK, Aronow BJ, Holtzman DM. (2001) Clusterin contributes to caspase-3 independent brain injury following neonatal hypoxia-ischemia. Nature Med. 7:338-343.

DeMattos RB, Bales KR, Cummins DJ, Dodart J-C, Paul SM, Holtzman DM. (2001) Peripheral anti-Ab antibody alters CNS and plasma Ab clearance and decreases brain Ab burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 98: 8850-8855:10.1073/pnas.151261398.

Han BH, D’Costa A, Back SA, Parsadanian M, Patel S, Shah AR, Gidday JM, Srinivasan A, Deshmukh M, Holtzman DM. BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia. Neurobiology of Disease 2000;7:38-53.

Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2000). Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2000;97:2892-2897.

Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizzary MC, Hyman BT. (2000) ApoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer’s disease. Ann Neurol 47:739-747.

Fagan AM, Younkin LH, Morris JC, Cole TG, Younkin SG, Holtzman DM. (2000) Differences in Ab 40/42 ratio associated with CSF lipoproteins as a function of apoE genotype. Ann. Neurol. 48:201-210.